ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Alnylam is a global commercial-stage biopharmaceutical company developing RNAi therapeutics. The company operates under its "Alnylam P 5 x25" strategy, aiming to become a top-tier biotech company by the end of 2025. As of the reporting date, Alnylam has four commercially approved products (ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO) and one product commercialized by a collaborator (Leqvio via Novartis).

Key Financial Metrics

Note: Q3 2023 included a one-time $310 million revenue recognition from the Roche collaboration and a $65 million catch-up adjustment from Regeneron, significantly inflating prior-year collaboration revenue.

Material Changes vs. Prior Period

• Revenue Composition Shift: Total revenue decreased 33% QoQ (Q3 2024 vs Q3 2023) primarily due to the absence of the $310 million upfront payment from Roche recognized in Q3 2023. However, Net Product Revenues increased 34% year-over-year, driven by strong growth in AMVUTTRA (+74% QoQ) and OXLUMO (+40% QoQ), partially offset by a decline in ONPATTRO (-38% QoQ) as patients switch to AMVUTTRA.
• Profitability: The company reported a net loss of $111.6 million for Q3 2024, compared to net income of $147.8 million in Q3 2023. The prior year income was driven by the non-recurring collaboration revenues mentioned above.
• Expense Growth: Operating expenses increased 8% QoQ to $577.8 million. Research and Development (R&D) expenses rose 7% to $270.9 million due to increased clinical trial activities for zilebesiran and mivelsiran. Selling, General, and Administrative (SG&A) expenses increased 11% to $221.0 million due to marketing investments.
• Liquidity: Cash, cash equivalents, and restricted cash increased to $1.10 billion as of September 30, 2024, up from $814.9 million at year-end 2023. Total liquid assets (including marketable securities) stand at approximately $2.78 billion.

Guidance, Outlook, and Risks

• Regulatory Milestones: In October 2024, Alnylam filed a supplemental New Drug Application (sNDA) with the FDA and a Type II Variation with the EMA for AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy, following positive HELIOS-B trial results.
• Collaboration Updates:
  • Roche: Received a $65 million milestone payment in April 2024 for dosing the first patient in the KARDIA-3 Phase 2 trial for zilebesiran.
  • Regeneron: In June 2024, amended the C5 License Agreement, granting Regeneron worldwide rights to cemdisiran monotherapy in exchange for a $10 million upfront payment and future milestones.
  • Novartis: Royalty revenue increased 136% QoQ due to higher global sales of Leqvio.
• Strategic Outlook: Management believes current cash and marketable securities are sufficient to fund operations for at least the next 12 months without additional equity financing. The company aims to achieve financial self-sustainability by the end of 2025.
• Risks and Contingencies:
  • Legal Proceedings: Ongoing patent infringement litigation against Pfizer/BioNTech and Moderna regarding mRNA vaccine lipids. A trial against Pfizer/BioNTech is scheduled for July 2025. The company reached a judgment of non-infringement with Moderna in October 2024, though Moderna has sought fee recovery.
  • Convertible Notes: $1.04 billion in 1% Convertible Senior Notes due 2027. Conversion conditions were not met in Q3 2024.
  • Development Derivative Liability: A liability of $421.9 million related to funding agreements with Blackstone Life Sciences increased due to fair value adjustments driven by positive clinical trial results.

Investor Verification Checklist

• AMVUTTRA Cardiomyopathy Approval: Verify the timeline and outcome of the FDA/EMA review for the new indication, which is critical for future revenue growth.
• Roche Collaboration Milestones: Monitor progress of the KARDIA-3 trial for zilebesiran to confirm eligibility for future milestone payments (up to $2.45 billion contingent).
• Leqvio Royalty Threshold: Track global sales of Leqvio to ensure the $1.0 billion threshold is met by December 31, 2029, to prevent an increase in the royalty share payable to Blackstone Royalties from 50% to 55%.
• Patent Litigation Status: Review updates on the Pfizer/BioNTech trial scheduled for July 2025 and the fee recovery motion filed by Moderna.
• Cost of Goods Sold (COGS): Monitor COGS as a percentage of revenue, which is expected to increase in 2024 due to higher royalty rates on AMVUTTRA sales, excluding one-time 2023 impairments.